Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

41.48 -0.02 (-0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
The Latest Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug. 
Via Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Apellis Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Apellis Pharmaceuticals
Via Benzinga
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
9 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Why Apellis Pharmaceuticals Stock Is Soaring Today
Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers. 
Via Benzinga
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and  
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Best Growth Stocks to Buy in April
Takeover interest is spurring these two biotech stocks higher. 
Via The Motley Fool
Apellis Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals, VirTra And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
The company's lead therapy was just approved for another indication. 
Via The Motley Fool
Why Apellis Pharmaceuticals Stock Surged This Week
A highly eventful five days for the company saw bulls pile into its shares. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.